Theriva Biologics Q2 EPS $(0.34) Down From $(0.31) YoY. Cash Bal $34.2M
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics reported Q2 losses of $(0.34) per share, a 9.68% decrease from $(0.31) per share in the same period last year. The company's cash balance stands at $34.2M.
August 08, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theriva Biologics' Q2 earnings per share decreased by 9.68% YoY, which could negatively impact the stock's performance.
Earnings per share (EPS) is a key indicator of a company's profitability. A decrease in EPS is generally seen as a negative sign by investors, which could lead to a decrease in the stock's price. Theriva Biologics' Q2 EPS decreased by 9.68% YoY, which could negatively impact investor sentiment and the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100